Kodiak Sciences Surges 178% After Both Eye Drugs Hit in Phase 3 DAYBREAK

Kodiak Sciences closed up 178% at $89.92 on Monday after both of its experimental eye drugs met the primary endpoint in the pivotal DAYBREAK trial in wet age-related macular degeneration — a result that positions the precommercial biotech for a three-indication filing in the fourth quarter and completes one of biotech's most dramatic comebacks: the stock traded at $3.26 in July 2023 after the company abandoned the same drug.

Both drugs hit — and the p-values are tiny

In DAYBREAK, a 675-patient, three-arm study, Zenkuda (tarcocimab tedromer) and tabirafusp-ted both demonstrated non-inferiority to aflibercept — Regeneron's Eylea — in best-corrected visual acuity at one year. Zenkuda's p-value was 0.0007; tabirafusp-ted's was 0.0036 on vision and under 0.0001 on the anatomical key secondary. The trial randomized patients 1:1:1 to the two Kodiak drugs or aflibercept, quadruple-masked, according to the clinicaltrials.gov registry.

The 54% number that moved the stock

The number the market seized on was durability: 54% of Zenkuda patients reached 24-week dosing intervals at year one — under what the company calls strict treat-to-dryness criteria, meaning any detectable retinal fluid on OCT triggered retreatment. Zenkuda is an anti-VEGF antibody-biopolymer conjugate with a claimed mean ocular half-life of about 20 days, roughly three times approved anti-VEGF therapies, designed for flexible dosing from one month to six.

A clean safety sheet, against history

Safety, the ghost of Kodiak's past, came back clean: zero intraocular inflammation and 0.5% cataract adverse events for Zenkuda, versus 0.9% cataract with aflibercept; tabirafusp-ted showed 0.4% inflammation and no cataract signal. That matters because inflammation and cataract imbalance killed the drug's first incarnation.

From $3.26: the redemption arc

The first incarnation died loudly. In February 2022, KSI-301 failed the DAZZLE wet-AMD study and the stock fell nearly 80% to $10.55. In July 2023, after twin GLEAM/GLIMMER diabetic-macular-edema failures with a 19%-versus-9% cataract imbalance, Kodiak abandoned tarcocimab entirely; shares fell by more than half to $3.26 on a $382 million market capitalization. What followed was a slow rebuild: a positive GLOW1 readout in late 2023, GLOW2 in March 2026 — 62.5% of patients with a two-step disease-severity improvement versus 3.3% on sham — and now DAYBREAK, the fifth positive Phase 3. Monday's close values the company at about $5.6 billion.

The honest caveats

The caveats are real. The aflibercept arm was dosed per label — standard 2 mg every eight weeks — not on a durability-optimized schedule, so the 24-week claim reflects regimen design as much as molecule. The topline disclosed no absolute letter gains and no non-inferiority margin; only p-values. Goldman Sachs, which resumed coverage at Neutral days before the readout with analyst Andrea Newkirk arguing positive results were ‘unlikely to meaningfully move shares,’ was proven wrong on the move — but her durable critique stands: tabirafusp-ted was tested on an eight-week schedule, and ‘matching Eylea on this timeline offers little value’ in a market moving to extended-interval drugs like Eylea HD and Vabysmo. Citi's Geoff Meacham added that cross-trial comparisons are imperfect and real-world durability unproven. And the balance sheet is thin: $125.9 million in cash at June 30, down from $209.9 million at year-end, with a formal going-concern warning and a $65.6 million quarterly loss.

What comes next

What comes next is a three-indication biologics license application in the fourth quarter of 2026 — wet AMD, diabetic retinopathy, and retinal vein occlusion — built on five positive Phase 3 studies, plus a December readout for KSI-101 in macular edema. Regeneron fell 3.8% on Monday; the $15 billion global retinal-disease market, by Kodiak's own estimate, just got a new contender. What remains unknown: the full visual-acuity data, whether regulators accept a single three-indication filing, and how the durability holds outside a trial protocol.